.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BF01_Acarbose.Acarbose .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BF01_Acarbose.Acarbose| name: | Acarbose | |
| ATC code: | A10BF01 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 0.32 | L |
| clearance: | 116 | mL/min |
| other parameters in model implementation | ||
Acarbose is an oral alpha-glucosidase inhibitor used to treat type 2 diabetes mellitus. It works by delaying the digestion and absorption of carbohydrates in the small intestine, thereby reducing postprandial blood glucose levels. It is approved and widely used for glycemic control in patients with diabetes.
Pharmacokinetic parameters from healthy adult volunteers, after oral administration.
Scheen, AJ, & Lefèbvre, PJ (1995). Antihyperglycaemic agents. Drug interactions of clinical importance. Drug safety 12(1) 32–45. DOI:10.2165/00002018-199512010-00003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7741982
Balaich, J, et al., & Donia, MS (2021). The human microbiome encodes resistance to the antidiabetic drug acarbose. Nature 600(7887) 110–115. DOI:10.1038/s41586-021-04091-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34819672
Jennings, PE (1997). Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus. Drugs & aging 10(5) 323–331. DOI:10.2165/00002512-199710050-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9143853